- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A GP complained that a Toviaz ad also promoted tolterodine without prescribing information. The Panel ruled a breach for missing obligatory information,…
A journal-lookalike supplement reporting a company-run symposium was presented as a sponsored independent forum report. The Panel ruled it was disguised promotion,…
A Champix journal ad claimed significantly greater quit success vs NiQuitin patch. PMCPA ruled the claim misleading because the ad didn’t explain…
A respiratory nurse complained about a sales manager’s personal Facebook/Instagram posts referencing a nurse KOL. Panel found one Instagram post in scope…
A nurse alleged she was suspended for refusing to share confidential unit/customer data from an infusion service facilitation programme. The Panel found…
Pfizer’s Toviaz ad claimed superiority vs tolterodine based on post hoc analysis and used “a new step” wording. PMCPA ruled multiple breaches…
A health professional alleged Cephalon reps promoted sublingual Effentora (off-licence). Panel found insufficient evidence on balance of probabilities; no breach of Clauses…
Anonymous GP alleged an AstraZeneca rep offered savings via his private consumables company, creating a perceived inducement/conflict. Panel had concerns about perception…
A Cipralex (escitalopram) journal ad said “For references and prescribing information, see overleaf” in text smaller than the Code’s 2mm requirement and…
Alcon’s Azarga leavepiece repeatedly used “comfort/comfortable”. Appeal Board allowed the comparative “Significantly more comfortable than Cosopt” claim (with data), but upheld breaches…
Anonymous key account manager alleged verbal contact-rate targets forced Code breaches. Panel found no evidence targets required excessive calls; company data suggested…
Three complaints about a 2004 Seroquel journal ad. PMCPA ruled the “only atypical… favourable weight profile across the full dose range” claim…
A British Pain Society poster/handout about Versatis included an “off-label” cost-saving conclusion. PMCPA ruled the poster was promotional, breached off-label and high-standards…
PMCPA ruled Pfizer in breach after two regional account directors had been in post for 2 years without passing the ABPI Medical…
PMCPA case summary: Anonymous non-contactable complainant vs PharmaMar (AUTH/2979/9/17). Case details, clauses, outcome and sanctions were not stated in the provided case…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.